Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psychiatric diseases

- PMLiVE

Cystic fibrosis group pledges $58m to Pfizer discovery programme

Pharma company forms public-private partnership with Cystic Fibrosis Foundation

- PMLiVE

J&J, Lilly and Merck join forces on clinical trials

Will set up database to improve efficiency of industry-sponsored drug trials

german flag

AZ sees Seroquel XR patent overturned in Germany

Follows challenge by Teva, Hexal and Accord Healthcare

- PMLiVE

Boehringer moves interferon-free hep C regimen into phase III

Oral combination drug achieved viral cure rate of up to 85 per cent in phase IIb

Pharma deals during October 2012

As pharma companies ramp up their activity after the summer, this month's dealmakers included Pfizer, AstraZeneca, Merck & Co and Bayer

- PMLiVE

Pfizer helps fund biotech venture from former researchers at closed Kent facility

Ziarco headed by former Pfizer chief scientific officer, allergy and respiratory research, Mike Yeadon

UK flag

MRC funds UK research using 22 AstraZeneca compounds

Provides £7m for projects covering Alzheimer’s, cancer, lung disease and rare conditions

- PMLiVE

Menarini signs €800m cancer antibody deal

Will work with Oxford BioTherapeutics on antibody-drug conjugates

- PMLiVE

AstraZeneca signs IBS collaboration with Ironwood in China

Deal will also see Ironwood’s US sales force promote Nexium for gastroesophageal reflux disease

- PMLiVE

Diabetes care recognised at UK awards

Joint working between pharma, NHS and patient organisations key among winners at QiC Diabetes 2012

Pharma deals during September 2012

In this regular review of deals we focus on transactions announced during September 2012

A new dogma in HTA assessment

New communication routes to HTA agencies are needed to ensure that these organisations can advise on clinical trial design

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links